Advances in the clinical laboratory assessment of urinary sediment.
Urinalysis has been used extensively in clinical practice to aid in the diagnosis of various renal and urologic diseases. The innovation of urinalysis is marching on right along with the rapid developments in biotechnology and astride from the solo urine cytology to sophisticated studies of individual component in the urinary sediment. In this review article, we focus on the use of flow cytometry and other technical advances in the examination of urinary sediment, the detection of urologic malignancies by the presence of microsatellite alteration in the urinary sediment, as well as the quantification of cytokine messenger RNA (mRNA) expression in urinary sediment by reverse transcription and real-time quantitative polymerase chain reaction (RT-QPCR). Notably, the study of cytokine mRNA expression in urinary sediment by RT-QPCR has recently been reported to provide important diagnostic information in kidney allograft recipients and patients with lupus nephritis. This simple and non-invasive method requires further study to determine its role in risk stratification and monitoring of therapeutic response in patients with other kidney diseases.
Chan
Rebecca Wing-Yan
RW
Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Szeto
Cheuk-Chun
CC
D016207:Cytokines / Q000652:urine; D004247:DNA / Q000652:urine; D005434:Flow Cytometry / Q000379:methods*; D006801:Humans; D007674:Kidney Diseases / Q000175:diagnosis* / Q000235:genetics / Q000652:urine*; D012333:RNA, Messenger / Q000235:genetics / Q000652:urine; D016482:Urinalysis / Q000379:methods*; D014556:Urine / Q000166:cytology
D016207:Cytokines; D012333:RNA, Messenger; D004247:DNA